Figure 2.
Changes in circulating T and lymphoma cells. CD4+ T cells in peripheral blood are decreased after initiation of cycle 1 rhIL-15 and mogamulizumab (A) with preferential depletion of CD4+ T cells with a phenotype consistent with ATLL (B).
Changes in circulating T and lymphoma cells. CD4+ T cells in peripheral blood are decreased after initiation of cycle 1 rhIL-15 and mogamulizumab (A) with preferential depletion of CD4+ T cells with a phenotype consistent with ATLL (B).
